The authors confirm that all data underlying the findings are fully available without restriction. Data is available from GenBank using accession number KC433553.

Introduction {#s1}
============

The recent emergence and spread of acquired carbapenem-resistance in gram-negative bacteria, which resulting in more clinical failures in infection control, have been increasingly reported. Carbapenem-resistant *Enterobacteriaceae* are usually resistant not only to β-lactam antibiotics but also to most other classes of antimicrobial agents [@pone.0111491-Centers1].

Resistance to carbapenems in gram-negative bacteria is frequently observed due to the high expression of AmpC β-lactamases, which are associated with the loss of outer membrane proteins [@pone.0111491-Cao1], the increased expression of efflux pumps systems [@pone.0111491-Wieczorek1], and with changes in the affinity of penicillin-binding proteins (PBPs) for carbapenems [@pone.0111491-Neuwirth1]. Carbapenem resistance can primarily be mediated by carbapenem-hydrolysing enzymes, such as metallo-β-lactamases (MBLs), Guiana extended-spectrum (GES) and *Klebsiella pneumoniae* carbapenemases (KPCs) [@pone.0111491-Nordmann1]--[@pone.0111491-WaltherRasmussen1].

KPC was first discovered in a *K. pneumoniae* clinical isolate collected from North Carolina in 2001 [@pone.0111491-Yigit1]. Thereafter, an amino acid variant of KPC-1, which is termed KPC-2, is discovered in *Klebsiella* spp. [@pone.0111491-SmithMoland1], [@pone.0111491-Yigit2] and *Salmonella enterica* [@pone.0111491-Miriagou1]. However, a recent correction of the *bla* ~KPC-1~ sequence have indicated that the sequences *of bla* ~KPC-1~ and *bla* ~KPC-2~ are identical, so, KPC-1 and KPC-2 are the same enzymes [@pone.0111491-Yigit1]. Mutations in the *bla* ~KPC-2~ gene have resulted in two variants, *bla* ~KPC-3~ [@pone.0111491-Woodford1] and *bla* ~KPC-4~ [@pone.0111491-Palepou1]. Since then, KPC have been detected in several members of *Enterobacteriaceae* and discovered in American, Asian, European and Near East regions [@pone.0111491-WaltherRasmussen1], [@pone.0111491-Maltezo1]--[@pone.0111491-Hawkey1].

Currently, sixteen different variants (KPC-2 to KPC-17) in the KPC family have been reported, and most current studies are focusing on KPC-2 and KPC-3 [@pone.0111491-Wolter1]--[@pone.0111491-Kitchel1]. In the study, we characterised phenotypic and enzymatic comparative analysis for the KPC-2 enzyme and novel KPC-15 variant which was discovered recently by us [@pone.0111491-Wang1].

Materials and Methods {#s2}
=====================

The ethics committee approval {#s2a}
-----------------------------

This study was approved by the the Ethics Committee of Municipal Hospital of Taizhou University, and the written informed consents obtained from each of the participants. The right of research objects was protected, and we agreed this study was conducted in our hospital.

Bacterial strains {#s2b}
-----------------

The two strains of *K. pneumoniae*, which were numbered Kp1769 and Kp1241, were isolated from samples of sputum and blood, respectively. The strain Kp1241 was isolated from the hepatobiliary unit in June 2012, and the strain Kp1769 was isolated from the ICU in September 2011 in respiration unit in the Taizhou Municipal Hospital of Taizhou University. The strain Kp1769, which was confirmed involving the *bla* ~KPC-2~ gene, was used to compare the characteristics of the kinetic parameters with the recently discovered *bla* ~KPC-15~ variant in this study. These two strains were assigned to *K. pneumoniae* using a Vitek GNI^+^ card (bioMérieux, France), and species identification was confirmed by a sequence analysis of the 16 S-23 S rRNA (Midi Labs, USA).

Antimicrobial susceptibility testing and conjugation experiments {#s2c}
----------------------------------------------------------------

The MICs of 20 antimicrobial agents, including imipenem, meropenem, ertapenem, ampicillin, aztreonam, cefazolin, cefepime, ceftazidime, ceftriaxone, ciprofloxacin, levofloxacin, amikacin, tobramycin, gentamicin, cephalosporin, ampicillin/sulbactam, piperacillin/tazobactam, cefoperazone/sulbactam, polymyxin B and colistin in the strains of *E. coli* J53Az^R^, Kp1241, Kp1769 and transconjugants, were determined using the Micro- Scan (USA) broth dilution method with plates. *Escherichia coli* ATCC 25922 and *Pseudomonas aeruginosa* ATCC 27853 were used as the controls. The results were interpreted according to CLSI (2012) [@pone.0111491-CLSI1].

According to a previously reported protocol [@pone.0111491-Wang2], conjugation experiments were performed in lysogeny broth (LB) with the strain *E. coli* J53Az^R^ (resistance to sodium azide) as the recipient and with the strains Kp1241 and Kp1769 as the donor strains. Donor and recipient cells in logarithmic phase (0.5 mL of each) were added to 4 mL of fresh LB, which was followed by incubation at 35°C for 18--24 h without shaking. The transconjugants were selected on trypticase soy agar (TSA) plates containing sodium azide (0.3 g/L) and imipenem (0.02 g/L) following incubation for 18--24 h at 35°C.

PCR amplification and sequencing {#s2d}
--------------------------------

PCR was performed for the amplification and sequencing of pre-*bla* ~KPC-15~, the *bla* ~KPC-15~ variant, and its surrounding genes (*bla* ~TEM~, *tnpA* and *tnpR*) in *K. pneumonae* using the primers shown in [Table 1](#pone-0111491-t001){ref-type="table"}. PCRs were also performed for the amplification of the transformant conjugated with *E. coli* J53Az^R^. The primers were synthesised by Sangon Biological Technology (Shanghai, China). The PCR conditions for pre-*bla* ~KPC-15~ and the *bla* ~KPC-15~ variant were as follows: 3 min at 94°C and 30 cycles of 1 min at 94°C, 1 min at 52°C, and 1 min at 72°C, followed by an elongation step for 10 min at 72°C, which produced a band of ca. 1,431 bp for *bla* ~KPC-15~, encompassing the entire KPC coding region. The same PCR conditions were used to amplify *bla* ~TEM~, *tnpA* (IS*Kpn8* and IS*Kpn6-*like transposases) and *tnpR* genes. The primers of tnpA~1~, tnpA~2~ and tnpA~3~ were used to amplify the IS*Kpn8* transposon, and the tnpA primer was used to amplify the IS*Kpn6-*like transposon. The positive PCR products were also sequenced by Sangon Biological Technology (Shanghai, China). Then, the sequencing results were assembled using the contigExpress Program software and the sequences were obtained for the genetic environment of the *bla* ~KPC-15~ variant from the strain Kp1241.

10.1371/journal.pone.0111491.t001

###### Sequences of primers utilised to determine the *bla* ~KPC~ genetic environment in this study.

![](pone.0111491.t001){#pone-0111491-t001-1}

  Primer                          Sequence (5′-3′)        Productsize (bp)                        reference
  ------------------------- ---------------------------- ------------------ -----------------------------------------------------
  pre-KPC-15                  For, ACTGGATGGAGGCGGATAA          700          The study (based on GenBank accession no. AY395881)
                              Rev, CACAGCGGCAGCAAGAAA                       
  pre-KPC-15 (sequencing)    For, TAAGCCCTCCCGTATCGTAG                       The study (based on GenBank accession no. AY395881)
                              Rev, TATCCGCCTCCATCCAGT                       
  KPC-15                     For, CGAGCAACTATGGATGAACG         1,431         The study (based on GenBank accession no. AY395881)
                              Rev, GTATCTGTGAGGGCGAAGG                      
  KPC-15 (sequencing)        For, CGGAACCATTCGCTAAACTCG                      The study (based on GenBank accession no. AY395881)
                             Rev, CGCCAACTCCTTCAGCAACA                      
  tnpA~1~                     For, ATCCGCATCGGGAAAGCC           1144         The study (based on GenBank accession no. JX500679)
                              Rev, CTGCTCGTCGGCAAAGGA                       
  tnpA~2~                    For, GCCAAGACACTGCTGCCTAA          1082         The study (based on GenBank accession no. JX500679)
                              Rev, TTGACGGAAGCGAAACACG                      
  tnpA~3~                    For, CAAGTTTCTGTCGGCCTTCA          1434         The study (based on GenBank accession no. JX500679)
                              Rev, CACGCCTTTGCTCCTGGGT                      
  tnpA                        For, ATACGCCATTCGCCTCAG           1320         The study (based on GenBank accession no. JX500679)
                              Rev, GTCGGCAAGGTGGTCTCA                       
  tnpR                        For, TCTTCGCAACACGCACCA           1834         The study (based on GenBank accession no. JX500680)
                              Rev, ACCTCGCCGTGGAAATAG                       
  TEM                         For, CTGTCTATTTCGTTCATCC          1061          The study (based on GenBank accession no. X64523)
                              Rev, CTCAGTATTGCCCGCTCC                       

Plasmids were isolated from the strain Kp1241 using an Axygen kit (USA) in accordance with the manufacturer's instructions. Plasmids were then separated by electrophoresis through a 0.6% agarose gel in the presence of 1× TBE buffer at a constant voltage of 90 V for 90 min. These plasmid DNA fragments served as samples for the amplification of *bla* ~KPC-15~ gene by PCR, where the initial position of the *bla* ~KPC-15~ gene plasmid was determined. The estimated sizes of plasmid DNAs were determined according to reference [@pone.0111491-Wang2]. Based on these data, we mapped the genetic sequence of the *bla* ~KPC-15~ upstream and downstream regions and determinded the start sites of transcription and the promoter regions of relevant genes.

β-lactamase preparation and the kinetic parameters for a comparison of KPC-15 and KPC-2 {#s2e}
---------------------------------------------------------------------------------------

Cultures of *K. pneumoniae* harboring *bla* ~KPC-15~ and *bla* ~KPC-2~ were grown overnight at 37°C in 100 ml of trypticase soy broth with amoxicillin (100 mg/mL). Bacterial suspensions were disrupted by sonication (20 s at 20 KHz×4 times) and centrifuged (30 min, 20,000 g, 4°C). The supernatants, which contained the crude enzyme extracts, were collected. Then, the crude enzyme extracts were mixed with 50 mM Tris-Cl, pH 7.4, with 1 mM magnesium sulphate, and lysed with 40 mg/L lysozyme. Next, 1.0 U/ml benzonase nuclease was added to digest nucleic acids, and a 2.0 mM concentration of EDTA was added to complete the periplasmic fractionation. The lysed cells were centrifuged at 12,000 rpm for 10 min to remove the cellular debris. The supernatant was further enriched and purified for β-lactamase by using preparative isoelectric focusing as described previously [@pone.0111491-Lin1], [@pone.0111491-Thomson1]. The β-lactamase purification step was performed in accordance with reference [@pone.0111491-PappWallac1].

Steady-state kinetic parameters were determined using a diode array spectrophotometer (Agilent, USA). Each assay was performed with 10 mM PBS, pH 7.4, at 25°C. In all assays, the enzyme was maintained at 10 nM, whereas substrate concentrations were varied from 50 to 200 µM. Kinetic assays were performed under steady-state conditions to determine the kms and kcats of the antimicrobial agents: imipenem, meropenem, ceftazidime, cefotaxime, cefepime, aztreonam and nitrocefin for the enzyme according to a previously established model represented in the kinetic parameter equation [@pone.0111491-Frere1], [@pone.0111491-Matagne1] and in reference [@pone.0111491-PappWallac1]. Concentrations varied from 25 to 250 µM for imipenem; 50 to 250 µM for meropenem; 150 to 500 µM for ceftazidime; 100 to 500 µM for cefotaxime; 250 µM to 1.5 mM for cefepime; and 50 mM to 500 mM for aztreonam. A final concentration of 100 µM nitrocefin was used as the reporter substrate.

Results {#s3}
=======

Antimicrobial susceptibility testing and conjugation experiment {#s3a}
---------------------------------------------------------------

The MICs of 20 antimicrobial agents for the strains Kp1241 and Kp1769 were depicted in [Table 2](#pone-0111491-t002){ref-type="table"}. The results suggested that the strain Kp1241 was resistant to 18 antimicrobial agents, and particularly exhibited high MIC values for imipenem, meropenem, and ertapenem at 16, 16, and 32 µg/mL, respectively; however, the strains Kp1769 showed MIC values for imipenem, meropenem, and ertapenem at 2, 2, and 4 µg/mL, respectively. And the strain Kp1241 remained susceptible to polymyxin B and colistin, so it was as the strain Kp1769. By the conjugation experiments, the transconjugant of strain Kp1241 exhibited a phenotype of resistance to imipenem, meropenem, ertapenem, cephalosporin, aminoglycosides, ampicillin/sulbactam, piperacillin/tazobactam and cefoperazone/sulbactam, but, the transconjugant of strain Kp1769 indicated intermedium values to imipenem, meropenem, and ertapenem. Hence, the results of conjugation experiments showed that the changes of MIC values of the antibiotics were due to the transferred plasmids.

10.1371/journal.pone.0111491.t002

###### The susceptibility for strains of *E. coli* J53Az^R^, Kp1241, Kp1769, and transconjugants (J53Az^R^-Kp1241 and J53Az^R^-Kp1769).

![](pone.0111491.t002){#pone-0111491-t002-2}

  Antimicrobial agent        MIC (µg/mL)                       
  ------------------------- ------------- ----- ------ ------- --------
  Ciprofloxacin                0.0025      16    0.25     4     0.0625
  Levofloxacin                 0.0025      16    0.25     8     0.625
  Amikacin                      0.25       128    2      32       1
  Tobramycin                    0.025      64     1      32      0.5
  Gentamicin                    0.25       32     1      16      0.5
  Ampicillin                    0.050      64    128     32       32
  Aztreonam                     0.50       128    2      32       1
  Cefotetan                    0.0125      128    64     32       16
  Cefazolin                     0.50       128    64     64       16
  Cefepime                     0.0125      128    1      32     0.625
  Ceftazidime                   0.050      16     2       8       1
  Ceftriaxone                   0.025      128    16     32       4
  Imipenem                      0.25       16     2       8       1
  Meropenem                     0.25       16     2       8       1
  Ertapenem                     0.50       32     4      16       2
  Ampicillin/Sulbactam          0.050      128    64     32       16
  Piperacillin/Tazobactam       0.025      256    16     64       4
  Cefoperazone/Sulbactam       0.0125      128    2      32      0.5
  Polymyxin B                   0.006      0.5   0.25   0.125   0.0625
  Colistin                     0.0125       1    0.5    0.25    0.125

Clinical breakpoints of MICs for the antimicrobial agents see the reference [@pone.0111491-CLSI1].

Amino acid variations, the minimum evolution tree of amino acid sequences and the kinetic parameters for KPC-15 and other KPC enzymes {#s3b}
-------------------------------------------------------------------------------------------------------------------------------------

Amino acid variations between novel *bla* ~KPC-15~ and other *bla* ~KPC~ genes were listed in [Figure 1](#pone-0111491-g001){ref-type="fig"}, and basing on the data of [Figure 1](#pone-0111491-g001){ref-type="fig"}, we drew the minimum evolution tree of amino acid sequences for KPC-2 to KPC-17 ([Figure 2](#pone-0111491-g002){ref-type="fig"}) using MEGA 5.05 software. The tree obviously indicated the KPC alleles evolution, and showed that the KPC-15 appeared to be homogenous with KPC-4 closely.

![Comparison of amino acid sequence alignments of KPC carbapenemases.\
KPC-15 was recently identified as a carbapenemase in *Klebsiella pneumonae* from the Taizhou Municipal Hospital of China. The data within parentheses are GenBank accession numbers.](pone.0111491.g001){#pone-0111491-g001}

![Minimum Evolution tree of amino acid sequences for KPC-2 to KPC-17.\
KPC-15 carbapenemase was our newly discovered and appeared to be homogenous with KPC-4 closely. The amino acid sequences of KPCs based on the data of [Figure 1](#pone-0111491-g001){ref-type="fig"}. This comparison was designed and analysed using MEGA 5.05 software.](pone.0111491.g002){#pone-0111491-g002}

Steady-state kinetic parameters were measured five times and averaged as shown in [Table 3](#pone-0111491-t003){ref-type="table"}. Consistent with the MIC data, the catalytic efficiency (kcat/km ratio) of the KPC-15 enzyme was lowest for ceftazidime, at 0.0142 µM^−1^ s^−1^, and was higher at 5.26-fold compared with that of the KPC-2 enzyme, at 0.0027 µM^−1^ s^−1^. However, the catalytic efficiency of the KPC-15 enzyme was highest for nitrocefin, at 9.2 µM^−1^ s^−1^, and was a little higher at 1.10-fold compared with that of the KPC-2 enzyme, at 8.4 µM^−1^s^−1^. The catalytic efficiency of the KPC-15 enzyme was higher at 2.96-fold for imipenem, with a value of 2.81 µM^−1^ s^−1^, compared with that of the KPC-2 enzyme, at 0.95 µM^−1^ s^−1^. Additionally, the catalytic efficiency of the KPC-15 enzyme was also higher at 2.72-fold for meropenem, with a value of 0.68 µM^−1^ s^−1^, compared with that of the KPC-2 enzyme, at 0.25 µM^−1^ s^−1^; the catalytic efficiency of KPC-15 enzyme was higher at 2.19-fold and 2.43-fold for cefotaxime and aztreonam, with values of 0.92 and 0.34 µM^−1^ s^−1^, respectively, compared with those values of the KPC-2 enzyme, at 0.42 and 0.14 µM^−1^ s^−1^, respectively, but higher at 2.01-fold for cefazolin, with a value of 5.62 µM^−1^ s^−1^, compared with that of the KPC-2 enzyme, at 2.8 µM^−1^ s^−1^. The quantitative values of the initial rate versus substrate concentration (v~0~/\[s\]) for KPC-15 and KPC-2 enzymes listed in [Table S1](#pone.0111491.s001){ref-type="supplementary-material"}. In general, the catalytic efficiency of KPC-15 was higher than that of KPC-2 for all tested antibiotics in this study ([Table 3](#pone-0111491-t003){ref-type="table"}).

10.1371/journal.pone.0111491.t003

###### Kinetic parameters for KPC-15 and KPC-2 enzymes.

![](pone.0111491.t003){#pone-0111491-t003-3}

  Substrate       KPC-15                    KPC-2                              
  ------------- ---------- ----------- ---------------- ---------- ----------- ----------------
  Imipene          69±3       194±2       2.81±0.54        21±2       20±1        0.95±0.65
  Meropenem      19.6±2.1   13.4±0.95     0.68±0.73      16.2±3.1   4.1±0.99      0.25±0.061
  Ceftazidime     192±8     2.73±0.91   0.0142±0.00074    217±6     0.59±0.83   0.0027±0.00056
  Cefotaxime      101±7       93±9        0.92±0.18       124±6       52±6        0.42±0.13
  Aztreonam       373±4       126±6       0.34±0.053      389±5       53±2        0.14±0.077
  Cefazolin        21±2       118±2       5.62±0.87        16±1       44±2         2.8±1.0
  Nitrocefin     5.2±1.1    47.6±3.2       9.2±0.96      6.5±2.4    54.7±4.1       8.4±0.34

PCR sequencing analysis and genetic organisation {#s3c}
------------------------------------------------

The analysis of the 8,997 bp nucleotide sequence for Kp1241 was shown in [Figure 3](#pone-0111491-g003){ref-type="fig"}. There were 5 different genes in the sequence, including the genes *tnpR*, *bla* ~TEM-12~ and *bla* ~KPC-15~, and the transposons IS*Kpn8* and IS*Kpn6*-like [@pone.0111491-Wang1]. The sites of the transcriptional promoters for the *bla* ~TEM-12~ and *bla* ~KPC-15~ genes were indicated as +1 and the −10 and −35 regions were also shown; however, there were no obvious transcriptional promoters in *tnpR*, IS*Kpn8* and IS*Kpn6*-like transposons. Between the *tnpR* gene and the IS*Kpn8* transposon, there was a 109 bp nucleotide interval; the IS*Kpn8* transposon nucleotide sequence was 3,020 bp. Between the IS*Kpn8* transposon and the *bla* ~TEM-12~ gene, there was a 206 bp nucleotide interval, which included the site of the transcriptional promoter for the *bla* ~TEM-12~ gene, +1 (*g*, start codon), −10 region (*tataac*) and −35 region (*ttattg*). Between the *bla* ~TEM-12~ and *bla* ~KPC-15~ genes, there was a 223 bp nucleotide interval, which included the site of the transcriptional promoter for the *bla* ~KPC-15~ gene, +1 (*g*, start codon), −10 region (*gattac*) and RBS (*aaggaa*, the ribosome binding site), but no obvious −35 region was shown in the *bla* ~KPC-15~ gene. Between the *bla* ~KPC-15~ gene and the IS*Kpn6*-like transposon, there was a 249 bp nucleotide interval, and the IS*Kpn6*-like transposon had a 1,320 bp nucleotide sequence.

![Promoter elements of the *bla* ~KPC-15~ and *bla* ~TEM~ genes in 8.997 kb-length nucleotide sequence.\
The sequence provided the upstream and downstream regions of *bla* ~KPC-15~ structural genes. The *tnpA* gene, which was upstream of the *bla* ~KPC-15~ (3,020 bp) gene, was homologous to a putative IS*Kpn8* transposon, and the downstream region of the *bla* ~KPC-15~ gene (1,320 bp) was homologous to a putative IS*Kpn6*-like transposon. The nucleotides upstream of the *bla* ~KPC-15~ and *bla* ~TEM-12~ gene translational start codons were shown in the box. The putative −10 promoter elements of the *bla* ~KPC-15~ gene were shown as *gattaa*, labeled as −10 below, and there were no obvious −35 promoter elements to be discovered in the promoter region. The putative −10 and −35 promoter elements of the *bla* ~TEM-12~ gene were shown as *tataac* and *ttattg*, labeled as −10 and −35 below the promoter region. The start sites of transcription were indicated as G by +1 residue. RBS was the abbreviation of the ribosome binding site.](pone.0111491.g003){#pone-0111491-g003}

Discussion {#s4}
==========

In recent years, many reports have described the presence of KPC β-lactamases (particularly KPC-2), and discovered they can cause resistance to carbapenem or reduce susceptibility to carbapenem in strains of the family of *Enterobacteriaceae* from different areas in China [@pone.0111491-Nordmann1], [@pone.0111491-Queenan1], [@pone.0111491-Mendes1]. It seems that KPC enzymes are becoming widely disseminated in China, and plasmids of different sizes may harbor the *bla* ~KPC-2~ gene [@pone.0111491-Shen1]. The genetic environments of the *bla* ~KPC~ gene have been characterised in some studies, and various transposon elements seems to be responsible for the rapid spread of *bla* ~KPC~ [@pone.0111491-Shen1]--[@pone.0111491-Wu1].

In this study, the susceptibility tests indicated that the strain Kp1241 showed resistance to quinolones, aminoglycosides, and the beta-lactam antibiotics, but susceptibility to polymyxin B and colistin with MICs of 0.5 and 1 µg/mL ([Table 2](#pone-0111491-t002){ref-type="table"}), respectively. This result suggested that the old antibiotics, polymyxin B and colistin, might play an important role in the treatment of the strain Kp1241 [@pone.0111491-Zavascki1].

Comparing the amino acids with other KPCs, KPC-15 showed more than two sites of amino acid changes (A119L and G146 K), and emerged to be homogenous with KPC-4 closly ([Figures 1](#pone-0111491-g001){ref-type="fig"} and [2](#pone-0111491-g002){ref-type="fig"}). The changes of the amino acids would influence the kinetic properties of the KPC enzymes. In spite of different values for the kms and kcats, the catalytic efficiency (kcat/km) of KPC-15 was higher than that of KPC-2 for all tested antibiotics ([Table 3](#pone-0111491-t003){ref-type="table"}). These data implied that the effect of KPC-15 caused resistance to β-lactam antibiotics (including imipenem, meropenem, ceftazidime, cefotaxime, aztreonam and cefazolin) was higher than that of KPC-2. Moreover, an evolutionary transformation changed KPC from an efficient carbapenemase to its variants (KPC-15) with better ceftazidimase catalytic efficiency. Because of the multi-resistance to quinolones or to aminoglycosides antibiotics, in addition to carbapenemase, the strain Kp1241 might involve other genes, such as quinolone or aminoglycoside genes.

According to the literature, there is a distinct genetic environment with the chimera of several transposon-associated elements in China, such as Tn*3*, IS*Kpn8* and an IS*Kpn6*-like element on plasmid pKP048 [@pone.0111491-Shen1]. With conjugation and gene mapping studies, we acquired three plasmids of different lengths. The *bla* ~KPC-15~ variant is on a ca. 73-kb plasmid and carries I*SKpn8* and an IS*Kpn6*-like element determinant [@pone.0111491-Wang1]. The transformant was also much less resistant than the original isolate, it was most likely due to the lack of any permeability lesion. The genetic environment of the *bla* ~KPC-15~ gene in the plasmid showed a structural and context similarity to those characteristics found in plasmid pKP048 [@pone.0111491-Shen1], except that a truncated *bla* ~TEM-12~ gene and the *bla* ~KPC-15~ variant were inserted and located between IS*Kpn8* and the novel *bla* ~KPC-15~ variant [@pone.0111491-Wang1]. The nucleotides upstream of the *bla* ~KPC-15~ translational start codon were also shown in [Figure 3](#pone-0111491-g003){ref-type="fig"}. The start codon was indicated as G by the +1 residue, and the putative −10 promoter elements were shown as *gattaa* and labeled as −10 below. These data were consistent with a study by Yigit et al. [@pone.0111491-Yigit1]; however, no obvious −35 region was discovered in the promoter region, which was different from previous report [@pone.0111491-Yigit1]. Only a 233 bp sequence was discovered between the *bla* ~TEM-12~ gene and the *bla* ~KPC-15~ variant in this study ([Figure 3](#pone-0111491-g003){ref-type="fig"}).

Conclusions {#s5}
===========

The study suggested that old antibiotics (polymyxin B and colistin) might play a role in therapy. The novel KPC-15 had more than two sites of amino acid changes (A119L and G146 K), and was homogenous with KPC-4 closly. The catalytic efficiency of KPC-15 causing resistance to β-lactam antibiotics was higher than that of KPC-2. Moreover, an evolutionary transformation changed KPC from an efficient carbapenemase to its variants (KPC-15) with better ceftazidimase catalytic efficiency.

Supporting Information {#s6}
======================
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**The quantitative values of the initial rate versus substrate concentration (v~0~/\[s\]) for KPC-15 and KPC-2 enzymes.**

(DOC)
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Click here for additional data file.
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